Pharmaceutical composition with improved dissolution property
US5091191A · kind A · utility
7Cited by
2References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 1989 |
| Grant date | Feb 25, 1992 |
| Priority date | — |
| Expiry date | Sep 25, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2054
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition of the active agent sodium 4-[.alpha.-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (a thromboxane synthetase inhibitor for treatment of diseases such as thrombosis and asthma) or its optical isomer or its hydrate with an improved dissolution property, which comprises D-mannitol and/or sodium hydrogencarbonate and at least one water-soluble polymer. The pharmaceutical composition is such that the dissolution of the above-mentioned active agent is free from pH dependency in the digestive tract including the stomach.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.